Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Conditions:   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Transformed Chronic Lymphocytic Leukemia;   Richter Syndrome Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Procedure: Bone Marrow Biopsy;   Procedure: Computed Tomography;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Ibrutinib;   Biological: Lisocabtagene Maraleucel;   Biological: Nivolumab;   Procedure: Phere sis;   Procedure: Positron Emission Tomography Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials